Companies of biotechnology in the massive health industry in the Beijing Economic and Technological Development Area (BDA) recently released 2020 operating results and fourth-quarter financial reports.

Many companies have achieved profit growth, which is attributed to their years of R&D investment and continuous product development.

Sanofi's financial report shows that in the fourth quarter of 2020, it turned losses into profits year-on-year, achieving a net profit of 1.09 billion euros ($1.32 billion) and total revenue of 9.38 billion euros in the fourth quarter.

General Electric also announced its 2020 fourth quarter and full year results. In the fourth quarter, its total revenue was $21.92 billion, and the quarterly net profit reached $2.44 billion, compared with $538 million in the same period last year. Its medical business revenue alone amounted to $4.82 billion.

The busy CT production line of GE Healthcare [Photo/kfqgw.beijing.gov.cn]

Kawin Technology disclosed its annual report on April 22. The company achieved operating income of 1.07 billion yuan in 2020, a year-on-year increase of 68.27 percent. The net profit attributable to shareholders of listed companies was 315 million yuan, a year-on-year increase of 68.67 percent.

Kawin Technology is officially listed on the Science and Technology Innovation Board. [Photo/kfqgw.beijing.gov.cn]

Earlier this month, JD Health and Bayer also released financial reports simultaneously. JD Health's total revenue in 2020 was 19.38 billion yuan, a year-on-year increase of 78.8 percent; Bayer Group's 2020 sales were 41.40 billion euros and the fourth quarter sales reached 99.95 billion euros.

Since the outbreak of the epidemic last year, BDA's biomedical companies have given full play to their advantages and promoted vigorous development of the industry through research and development of new drugs. 

Meanwhile, the BDA also provides assistance to key enterprises through a normalized enterprise service mechanism.

In the first quarter of this year, the total output value of industries above designated size in the BDA reached 139.80 billion yuan, an increase of 47.4 percent year-on-year. 

As for one of the four leading industries, the biotechnology and massive health industry, its year-on-year growth rate reached 155.30 percent from January to February.